HCM vs ONC: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ONC is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HCM and ONC share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HCM and ONC exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

HUTCHMED (China) Limited trades on Nasdaq as ADSs under HCM, on the Hong Kong Stock Exchange as stock code 13, and on London's AIM market. It discovers and develops targeted oncology and immunology therapies in China and increasingly commercializes them globally through partners. Its marketed portfolio includes fruquintinib (sold as ELUNATE in China with Eli Lilly and as FRUZAQLA outside China with Takeda), surufatinib (SULANDA) for neuroendocrine tumors, and savolitinib (ORPATHYS) partnered with AstraZeneca. A separate Other Ventures segment, mainly prescription drug distribution in China, contributed ~$116 million of revenue in the first half of 2026 and is a lower-margin, non-innovative business that inflates headline revenue relative to the drug franchise.

Full HCM guide

BeOne Medicines is a global oncology company built around one large drug. BRUKINSA (zanubrutinib), a BTK inhibitor used in chronic lymphocytic leukemia and other B-cell cancers, produced ~$1.2 billion of the ~$1.68 billion in product revenue it booked in the second quarter of 2026. Around it sit TEVIMBRA (tislelizumab), a PD-1 antibody; BEQALZI (sonrotoclax), a BCL2 inhibitor that won U.S. accelerated approval in relapsed or refractory mantle cell lymphoma; ZIIHERA (zanidatamab) in HER2-positive gastroesophageal cancer; and in-licensed Amgen products sold in China. The company was BeiGene until recently. Its Nasdaq listing began trading under symbol ONC instead of BGNE on January 2, 2025, and effective May 27, 2025 the company moved its jurisdiction of incorporation from the Cayman Islands to Switzerland and took the BeOne Medicines name. What a U.S. holder actually owns is an American Depositary Share representing 13 ordinary shares, the same shares listed in Hong Kong (06160) and, as RMB shares, on Shanghai's STAR Market (688235).

Full ONC guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HCM drivers: ATTC platform licensing as the value unlock; China commercial rebound and fruquintinib's geographic spread.
• ONC drivers: BRUKINSA taking share in B-cell cancers; Costs growing slower than revenue.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Most of HUTCHMED's product economics run through partners, so Takeda, Eli Lilly and AstraZeneca decisions on pricing, launch pace and promotion shape results more than HUTCHMED's own execution does. For ONC, concentration is the central issue: BRUKINSA is roughly 70% of product revenue, so any label setback, reimbursement change or successful patent challenge lands directly on the whole business.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick HCM if you believe its drivers more; ONC if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HCM and ONC guides.

HCM. The headline revenue number is misleading on its own because ~$116 million of first-half 2026 revenue came from the low-margin Other Ventures drug distribution segment rather than innovative medicines; the oncology and immunology franchise generated ~$162.3 million, of which ~$40.9 million was milestone, royalty and R&D service income including an ~$18.1 million payment from Eli Lilly. Profitability is genuine but slim, with R&D of ~$78.8 million in the half consuming most of the gross profit. Because net cash covers roughly half the market value, valuation multiples on the operating business look far lower than a screener showing price-to-sales on the consolidated figure would suggest.

ONC. Figures come from the Form 10-Q for the quarter ended June 30, 2026 and the accompanying Q2 2026 earnings release filed with the SEC on August 5, 2026. The company reports in U.S. dollars, so no conversion is involved despite the Swiss domicile and the Hong Kong and Shanghai listings. Note that per-ADS figures are 13 times the per-ordinary-share figures, which is why a screener showing EPS of $0.16 and one showing $2.12 can both be right.

Headline figures (approximate, September 2026): HCM shows market capitalization ~$2.4B (ADS ~$14, ~173M ADSs, each ADS = 5 ordinary shares), revenue (ttm) ~$549M (FY2025 ~$548.5M; H1 2026 ~$278.3M vs ~$277.7M in H1 2025), net income attributable (ttm) ~$18M (H1 2026 ~$15.9M; the ~$455M H1 2025 figure was mostly a one-off SHPL divestment gain), cash and short-term investments ~$1.37B at June 30, 2026, against ~$95M of bank borrowings; ONC shows revenue (ttm) ~$6.13B, q2 2026 revenue ~$1.71B, up ~30% year over year, gaap net income (ttm) ~$656M (FY2025 was ~$287M, FY2024 a ~$645M loss), q2 2026 diluted eps per ads ~$2.05 GAAP, ~$3.84 adjusted.

HCM and ONC are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HCM and ONC exposure against your real portfolio. It is not an investment adviser.